Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1CNS 1

Conditions

Glioblastoma 1Endometrial Adenocarcinoma 1Advanced Cancer 1

Interventions

pembrolizumab 1265Specimen Handling 926Magnetic Resonance Spectroscopy 830Carboplatin 823Cyclophosphamide 800Cisplatin 723Nivolumab 669Paclitaxel 627Radiotherapy 611Gemcitabine 573Biopsy 557Bevacizumab 478Dexamethasone 438fludarabine 407Docetaxel 380venetoclax 368Oxaliplatin 364Capecitabine 358Fluorouracil 355atezolizumab 350durvalumab 332Rituximab 330Drug Therapy 326Doxorubicin 316Radiosurgery 315Standard of Care 309Blood Specimen Collection 308Pemetrexed 305Ipilimumab 299Radiation 286

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
linrodostat × 1 year × Clear all
NCT03459222 2026-04-06

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Bristol-Myers Squibb

Phase 1/2 Completed
229 enrolled 21 charts

Advanced Cancer

NCT04106414 2025-10-14

Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
24 enrolled
GynecologicSarcoma

Endometrial Adenocarcinoma

NCT04047706 2025-06-29

Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Northwestern University

Phase 1 Active not recruiting
18 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡